Redeye provides a short comment on Scandinavian ChemoTech announcing sales of USD390k in the second quarter. Although record-breaking, the performance was mostly in line with our estimates. Still, it is reassuring to see that the strong momentum from the start of the year continues. We leave our estimates and valuation untouched.
LÄS MER